

identical chemical structure to lovastatin.³ Thus, although RYR is claimed to be a safer alternative to regular statins, structural similarity with lovastatin implies that similar adverse reactions can be expected. Furthermore, monacolin content is not standardized among marketed products and are generally not depicted on labels.⁴ Indeed, a study assessing monacolin content in 12 commercial RYR formulations labeled as “600 mg/capsule of active product” found marked variability, ranging from 0.10 to 10.09 mg of monacolin per capsule, challenging the efficacy and safety of the product.⁵ In our case, the label stated that monacolin K content was at least 10 mg per capsule.

The U.S. Food and Drug Administration (FDA) has ruled that RYR with more than trace amounts of monacolin K cannot be sold as dietary supplements, which is not the case of the European Food Safety Authority (EFSA).

There are isolated case-reports of over-the-counter RYR hepatotoxicity, all of them are mild-to-moderate in severity and self-limited in course, which are consistent with the one presented in this report. For this reason, taking into account that HDS are easy-to-obtain products, considered safe for most people, contain multiple active ingredients in poorly specified amounts and with incomplete labeling, safety can very well be compromised. Therefore, physicians must remain alert that HDS might be the cause of acute liver injury in some patients.

Conflict of interest

XF has acted as advisor for Abbvie and Gilead. GS has nothing to report.

References

1. Hoofnagle JH, Björnsson ES. Drug-induced liver injury – types and phenotypes. *N Engl J Med.* 2019;381:264–73.
2. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. *Hepatology.* 2010;52:2065–76.
3. Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. *Nat Rev Endocrinol.* 2017;13:278–88.
4. Gerard MC, Terlouw RJ, Yu H, Koks CHW, Gerdes VEA. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – a systematic review and meta-analysis. *Atherosclerosis.* 2015;240:415–23.
5. Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice. *Arch Internal Med.* 2010;170:1722–7.

Guillem Soy^a, Xavier Forn^{a,b,*}

^a *Liver Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain*

^b *Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain*

* Corresponding author.

E-mail address: xforns@clinic.cat (X. Forn).

<https://doi.org/10.1016/j.gastrohep.2020.06.033>

0210-5705/ © 2020 Elsevier España, S.L.U. All rights reserved.

Surgery and emergency gastrointestinal endoscopy during the Covid-19 pandemic



Cirugía y endoscopia gastrointestinal de emergencia durante la pandemia de Covid-19

Urgent gastrointestinal endoscopy (UGE) is a worldwide extended medical procedure, being the most frequent the upper and lower gastrointestinal bleeding and impaction of a foreign body the most common emergencies that require this technique.^{1,2} The activity in endoscopy units has been deeply affected by Covid-19 pandemic. In order to decrease the risk of infection, elective endoscopy has been stopped since “State of Alarm” was declared. However this restriction does not apply to UGE.

We analyzed the UGEs that have been performed from March 1st 2020 to April 30th 2020 and compared with those performed during the same period in the previous year (2019; pre-Covid period).

The UGE is usually performed in our hospital (Donostia University Hospital) from Monday to Friday between 3 p.m and 8 p.m and Saturday/Sunday during all the day. UGE are usually requested by the Emergency Department and less frequently from hospitalization rooms or intensive care unit.

Regarding our protocol, we routinely perform the UGE within the 12h after admission to patients with gastrointestinal bleeding and within 6h to those with impaction of foreign bodies.

In total 126 UGE were included of which 107 (85%) were upper endoscopy. Upper bleeding was the most common clinical indication in 56 patients (44%), while impaction of a foreign body was the second most common reason for indication reported in 47 cases (37%) (Table 1). On the other hand, lower gastrointestinal bleeding was the main indication for urgent colonoscopy, performed in 11 (9%) cases, followed by 6 patients (5%) who needed stenting due to colonic obstruction related with colorectal cancer. Sixty-four procedures (51%) were performed either in Saturday or Sunday (Table 1).

Comparing the two periods, a reduction of 44% in UGE procedures was observed in the Covid period (45 Covid period vs. 81 pre-Covid). In addition, upper endoscopy was significantly more common in proportion than colonoscopy in the Covid period, 89% (40/45) vs. 83% (67/81). The number of UGE by upper gastrointestinal bleeding fell from 33 patients in the pre-Covid period to 23 patients in the Covid period, therefore constituting a reduction in 30%. In impaction of foreign bodies, a 58% decrease was observed: from 33 in the pre-Covid period to 14 during the pandemic. The percentage of emergency endoscopies that

Table 1 Type of urgent gastrointestinal endoscopies performed in the months of March and April 2019 and 2020 and the distribution of endoscopies throughout the days of the week.

	2019 (85 patients)	2020 (45 patients)	Variation %
<i>Upper gastrointestinal bleeding</i>	33	23	−30%
<i>Foreign bodies</i>	33	14	−58%
<i>Others upper gastrointestinal endoscopies*</i>	5	3	−40%
<i>Lower gastrointestinal bleeding</i>	8	3	−62%
<i>Colonic stent</i>	4	2	−50%
<i>Others lower gastrointestinal endoscopies**</i>	2	0	−100%
Therapeutic endoscopic interventions	40	21	−47%
Acute bleeding	8 (8 upper)	6 (5 upper)	−25%
Foreign body removal	25	12	−52%
Others***	7	3	−57%
Days of the week	2019 (85 patients)	2020 (45 patients)	
Monday	12	4	−67%
Tuesday	7	3	−57%
Wednesday	11	5	−55%
Thursday	7	4	−43%
Friday	8	5	−38%
Saturday	18	11	−39%
Sunday	22	13	−41%

* Epigastric pain.

** Volvulus.

*** Stent, devolvulation.

Table 2 General data of the hospital in the months of March and April 2019, compared to the same period in 2020.

	2019	2020	Variation %
<i>Patients admitted in hospital</i>	7952	5059	−36%
<i>Elective surgery (all Departments)</i>	2509	1313	−48%
<i>Emergency surgery (all Departments)</i>	628	517	−18%
<i>Elective general surgery</i>	525	262	−50%
<i>Emergency general surgery</i>	194	143	−26%
Appendectomy	47	29	−38%
Anorectal abscess	37	22	−41%
Cholecystectomy	27	16	−41%
Abdominal wall hernia	14	17	+21%
Gastrointestinal perforation	5	7	+40%
Others*	64	52	−19%
Died**	514	735	+43%

* Vacuum pack technique, intestinal obstruction, abdominal ischemia, volvulus, peritonitis, etc.

** Died in our area (Donostialdea). These are approximate data and have been obtained in internal records.

required some therapeutic procedure went from 47% (40/85) in the pre-Covid period to 47% (21/45) in the Covid period (Table 1). The number of colonoscopies needed for colonic stents in obstructive colorectal cancer decreased by half during the Covid period. It is to be noted that the decrease in the number of procedures was higher from Monday to Friday than on weekends (53% vs. 40%) (Table 1).

As a result of the collapse of the emergency departments and hospitals, healthcare authorities strongly suggested the population to stay at home and to avoid going to primary healthcare centers or to emergency departments, if it wasn't essential. The number of hospital admission and elec-

tive surgery decreased a 36% and 48%, respectively (Table 2). This fact is one of the main reasons to explain the decrease on the demand for UGE in hospitals. We assume that, in our environment, many UGE do not need any therapeutic maneuver, they are just diagnostic explorations. More than half of the emergency endoscopies were conducted with diagnostic purposes, without changes in both periods (53%). Probably most of these patients presenting with melena or rectal bleeding in the current "State of Alarm," minimized their symptoms and waited longer before attending healthcare systems. Probably, in some cases, symptoms spontaneously disappeared. In general emergency, surgery

experienced a similar pattern and the number of appendectomy, abscess, or cholecystectomy decreased between 38% and 41%. It's possible that antibiotics were used more frequently in the Covid period. Another consequence of this may be an increase in gastrointestinal perforations (Table 2).

Similarly, people suffering from impaction of foreign bodies could also have waited a longer time to ask for medical attention or could have tried different attempts to solve the impactation, such as drinking carbonated beverages. Spending more time at home and having more time to eat could be another reason to explain the reduction of impactions. Probably related to the former reasons the percentage decrease of UGE due to impaction of foreign bodies was higher than the observed for GI bleeding.

On the other hand, decreased demand from hospitalization rooms may be another explanation for the reduction in the number of UGE performed. In fact, during the COVID-19 period, non-urgent surgical activity was lower, therefore the number of post-surgical complications decreased (Table 2).

There is no obvious explanation for the decrease in the treatment of colonic obstruction or volvulus, but it could be related to the probable increase of acute abdomen and peritonitis.

According to our experience, the decrease in UGE was lower on weekdays than on weekends. Perhaps the endoscopy was delayed until the next morning trying to avoid coronavirus infections.

In summary, during the Covid period, an important decrease in the emergency endoscopy and surgery was observed.

Contributions

IG and LB developed the study concept and design and drafted the manuscript. LB, PA, IG, ST, MM, JMN acquired the clinical data, designed and analyzed the database and

interpreted the data. LB and IG carried out the statistical analysis of data and contributed to the interpretation of data. All had the opportunity to revise the manuscript.

Acknowledgements

We thank Arantza Zubizarreta, Javier Basterrechea and Nieves Gonzalez-García for his kind collaboration in this study.

References

1. Duran A, Ocak T, Oztürk H. Emergency upper gastrointestinal endoscopy at the Emergency Department of İzzet Baysal Hospital: analysis of 263 patients. *Med Glas (Zenica)*. 2013;10:144–7.
2. Anderson KL, Dean AJ. Foreign bodies in the gastrointestinal tract and anorectal emergencies. *Emerg Med Clin North Am*. 2011;29:369–400.

Luis Bujanda^{a,*}, Paula Arratibel^{a,b}, Ines Gil^{a,b}, Silvia Torrente^{a,b}, Maider Martos^{a,b}, Jose M. Enriquez-Navascues^b

^a Department of Gastroenterology, Hospital University Donostia, Instituto Biodonostia, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), San Sebastián, Spain

^b Department of Surgery, Hospital University Donostia, Instituto Biodonostia, Spain

* Corresponding author.

E-mail address: medik@telefonica.net (L. Bujanda).

<https://doi.org/10.1016/j.gastrohep.2020.07.002>
0210-5705/ © 2020 The Authors. Published by Elsevier España, S.L.U.

El ustekinumab en la profilaxis de la recurrencia posquirúrgica: Nuestra experiencia clínica



Ustekinumab for prevention of postoperative recurrence: Our clinical experience

En la enfermedad de Crohn (EC), la recurrencia posquirúrgica (RPQ) es un acontecimiento frecuente. En ausencia de tratamiento, el 65-90% de los pacientes intervenidos presentan recurrencia endoscópica el primer año posquirugía, y el 80-100% a los tres años¹.

Según las indicaciones actuales de la ECCO, se recomienda el tratamiento profiláctico de RPQ tras una intervención en pacientes con al menos un factor de riesgo. Los fármacos de elección son las tiopurinas, o los antiTNF, siendo los salicilatos y los antibióticos alternativas terapéuticas útiles en casos aislados^{2,3}.

No existe evidencia ni descripción en la literatura del uso de ustekinumab (USTK), como tratamiento preventivo

de la RPQ. A continuación, presentamos nuestra experiencia clínica sobre el uso de USTK, para profilaxis de la RPQ en la EC.

Material y métodos

Describimos una serie de tres pacientes tratados con ustekinumab como profilaxis de la RPQ, todos ellos con EC de larga evolución con patrón estenosante y /o fistulizante, necesidad de una o varias resecciones quirúrgicas y tratamiento previo con dos antiTNF e inmunosupresores como características comunes.

Se ha valorado la RPQ mediante: endoscopia, entero-RM y biomarcadores (calprotectina fecal, proteína c reactiva, VSG y leucocitos).

Caso 1

Paciente de 50 años, fumadora, con EC A2L1B2 de 12 años de evolución. Precisó la primera resección quirúrgica a los